市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | GH Research PLC | 看涨 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.00 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 40.39% |
| 机构持股比例 | 59.15% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bvf Inc/Il | 30 Sep 2024 | 10,400,158 |
| Lynx1 Capital Management Lp | 30 Sep 2024 | 4,195,894 |
| Verition Fund Management Llc | 30 Sep 2024 | 1,057,782 |
| Cormorant Asset Management, Lp | 30 Sep 2024 | 593,043 |
| 5Am Venture Management, Llc | 30 Sep 2024 | 572,665 |
| Peak6 Investments Llc | 30 Sep 2024 | 74,267 |
| Alps Advisors Inc | 30 Sep 2024 | 38,362 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (HC Wainwright & Co., 122.35%) | 购买 |
| 中 | 34.00 (88.99%) | |
| 低 | 28.00 (Canaccord Genuity, 55.64%) | 购买 |
| 平均值 | 34.00 (88.99%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 9.14 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Jan 2025 | 40.00 (122.35%) | 购买 | 8.81 |
| 13 Jan 2025 | 40.00 (122.35%) | 购买 | 8.35 | |
| Canaccord Genuity | 18 Nov 2024 | 28.00 (55.64%) | 购买 | 9.47 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合